{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:49:48Z","timestamp":1780447788432,"version":"3.54.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2006,6,1]]},"DOI":"10.1038\/ncpneph0189","type":"journal-article","created":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T19:40:37Z","timestamp":1149277237000},"page":"326-336","source":"Crossref","is-referenced-by-count":15,"title":["Reappraisal of 2003 NKF-K\/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients"],"prefix":"10.1038","volume":"2","author":[{"given":"Matthieu","family":"Monge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Shahapuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Oprisiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeh","family":"El Esper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Morini\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneph0189_CR1","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2003) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 13): S1\u2013S201","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"BFncpneph0189_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1525-139X.2005.18318.x","volume":"18","author":"I Shahapuni","year":"2005","unstructured":"Shahapuni I  et al. (2005) How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18: 226\u2013238","journal-title":"Semin Dial"},{"key":"BFncpneph0189_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA  et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR4","first-page":"1840","volume":"86","author":"A Fournier","year":"2001","unstructured":"Fournier A  et al. (2001) Optimal range of plasma concentration of true 1-84 parathyroid hormone in patients on maintenance dialysis. J Clin Endocrinol Metab 86: 1840\u20131842","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0189_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1172\/JCI106529","volume":"50","author":"AE Fournier","year":"1971","unstructured":"Fournier AE  et al. (1971) Etiology of hyperparathyroidism and bone disease during chronic hemodialysis: I. Association of bone disease with potentially etiologic factors. J Clin Invest 50: 592\u2013598","journal-title":"J Clin Invest"},{"key":"BFncpneph0189_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1172\/JCI106530","volume":"50","author":"AE Fournier","year":"1971","unstructured":"Fournier AE  et al. (1971) Etiology of hyperparathyroidism and bone disease during chronic hemodialysis: II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 50: 599\u2013605","journal-title":"J Clin Invest"},{"key":"BFncpneph0189_CR7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/j.1523-1755.2005.310_1.x","volume":"67","author":"M Touam","year":"2005","unstructured":"Touam M  et al. (2005) High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney Int 67: 2065","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR8","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA  et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516\u20131525","journal-title":"N Engl J Med"},{"key":"BFncpneph0189_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1046\/j.1523-1755.1999.00480.x","volume":"55","author":"A Ghazali","year":"1999","unstructured":"Ghazali A  et al. (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55: 2169\u20132177","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","volume":"18","author":"T Sadek","year":"2003","unstructured":"Sadek T  et al. (2003) Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18: 582\u2013588","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0189_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5414\/CNP64288","volume":"64","author":"I Mucsi","year":"2005","unstructured":"Mucsi I  et al. (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64: 288\u2013294","journal-title":"Clin Nephrol"},{"key":"BFncpneph0189_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/228764a0","volume":"228","author":"DR Fraser","year":"1970","unstructured":"Fraser DR and Kodicek E (1970) Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 228: 764\u2013766","journal-title":"Nature"},{"key":"BFncpneph0189_CR13","doi-asserted-by":"crossref","unstructured":"Dusso AS (2003) Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl: S6\u2013S9","DOI":"10.1046\/j.1523-1755.63.s85.3.x"},{"key":"BFncpneph0189_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1359\/jbmr.2003.18.7.1217","volume":"18","author":"R Masuyama","year":"2003","unstructured":"Masuyama R  et al. (2003) Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption. J Bone Miner Res 18: 1217\u20131226","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0189_CR15","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1073\/pnas.131029498","volume":"98","author":"DK Panda","year":"2001","unstructured":"Panda DK  et al. (2001) Targeted ablation of the 25-hydroxyvitamin D 1\u03b1-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98: 7498\u20137503","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneph0189_CR16","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1046\/j.1523-1755.2001.00042.x","volume":"60","author":"M Cozzolino","year":"2001","unstructured":"Cozzolino M  et al. (2001) p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60: 2109\u20132117","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR17","volume-title":"Spectrum of Renal Osteodystrophy","author":"J Silver","year":"2001","unstructured":"Silver J  et al. (2001) Regulation of PTH secretion and synthesis and of parathyroid cell proliferation. In Spectrum of Renal Osteodystrophy, 25 (Eds Dr\u00fccke T and Salusky I) Oxford: Oxford University Press"},{"key":"BFncpneph0189_CR18","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1359\/jbmr.2002.17.12.2206","volume":"17","author":"CS Ritter","year":"2002","unstructured":"Ritter CS  et al. (2002) Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 17: 2206\u20132213","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0189_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00355.x","volume":"65","author":"SC Schiavi","year":"2004","unstructured":"Schiavi SC and Kumar R (2004) The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65: 1\u201314","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","volume":"67","author":"S Nakanishi","year":"2005","unstructured":"Nakanishi S  et al. (2005) Serum fibroblast growth factor-23 levels predict future refactory hyperparathyroidism in dialysis patients. Kidney Int 67: 1171\u20131178","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.ki.5000020","volume":"69","author":"N Nagano","year":"2006","unstructured":"Nagano N  et al. (2006) Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69: 531\u2013537","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR22","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1093\/ndt\/gfg374","volume":"18","author":"P Jolma","year":"2003","unstructured":"Jolma P  et al. (2003) Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure. Nephrol Dial Transplant 18: 2560\u20132569","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0189_CR23","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/j.1523-1755.2004.66006.x","volume":"66","author":"I Porsti","year":"2004","unstructured":"Porsti I  et al. (2004) High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int 66: 2155\u20132166","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR24","first-page":"2967","volume":"87","author":"U Segersten","year":"2002","unstructured":"Segersten U  et al. (2002) 25-hydroxyvitamin D3-1\u03b1-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87: 2967\u20132972","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0189_CR25","first-page":"a750","volume":"16","author":"CS Ritter","year":"2005","unstructured":"Ritter CS  et al. (2005) 25 hydroxyvitamin D3 suppresses PTH synthesis and secretion by cultured bovine parathyroid cells: potential role for intracrine1.25(OH)2 D3. J Am Soc Nephrol 16: a750 (Poster SA PO 889)","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1172\/JCI17416","volume":"111","author":"CH Kos","year":"2003","unstructured":"Kos CH  et al. (2003) The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111: 1021\u20131028","journal-title":"J Clin Invest"},{"key":"BFncpneph0189_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1172\/JCI200317054","volume":"111","author":"Q Tu","year":"2003","unstructured":"Tu Q  et al. (2003) Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 111: 1029\u20131037","journal-title":"J Clin Invest"},{"key":"BFncpneph0189_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","volume":"67","author":"M Colloton","year":"2005","unstructured":"Colloton M  et al. (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67: 467\u2013476","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR29","first-page":"318","volume-title":"Proceedings of the ERA XLI Congress; Lisbon","author":"D Martin","year":"2004","unstructured":"Martin D  et al. (2004) Regression of parathyroid hyperplasia by cinacalcet Hcl in a rodent model of chronic kidney disease. In Proceedings of the ERA XLI Congress; Lisbon, 318 (Poster MP262)"},{"key":"BFncpneph0189_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1210\/jcem-61-4-601","volume":"61","author":"F Llach","year":"1985","unstructured":"Llach F and Massry SG (1985) On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601\u2013606","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0189_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI113172","volume":"80","author":"AA Portale","year":"1987","unstructured":"Portale AA  et al. (1987) Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus: implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 80: 1147\u20131154","journal-title":"J Clin Invest"},{"key":"BFncpneph0189_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00005792-194305000-00002","volume":"22","author":"S Liu","year":"1943","unstructured":"Liu S and Chu H (1943) Studies of calcium phosphate metabolism with special reference to pathogenesis and effects of dihydrotachysterol and iron. Medicine 22: 103\u2013161","journal-title":"Medicine"},{"key":"BFncpneph0189_CR33","first-page":"S178","volume":"24","author":"A Fournier","year":"1988","unstructured":"Fournier A  et al. (1988) Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int Suppl 24: S178\u2013S179","journal-title":"Kidney Int Suppl"},{"key":"BFncpneph0189_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/ki.1992.407","volume":"42","author":"MH Lafage","year":"1992","unstructured":"Lafage MH  et al. (1992) Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42: 1217\u20131225","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"NA Hamdy","year":"1995","unstructured":"Hamdy NA  et al. (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358\u2013363","journal-title":"BMJ"},{"key":"BFncpneph0189_CR36","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/ndt\/10.12.2228","volume":"10","author":"E Ritz","year":"1995","unstructured":"Ritz E  et al. (1995) Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure. Nephrol Dial Transplant 10: 2228\u20132234","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0189_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000183396","volume":"39","author":"P Morini\u00e8re","year":"1985","unstructured":"Morini\u00e8re P  et al. (1985) Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39: 309\u2013315","journal-title":"Nephron"},{"key":"BFncpneph0189_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1046\/j.1523-1755.2000.00819.x","volume":"57","author":"OS Indridason","year":"2000","unstructured":"Indridason OS and Quarles LD (2000) Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients: Durham Renal Osteodystrophy Study Group. Kidney Int 57: 282\u2013292","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1096\/fj.05-5432fje","volume":"20","author":"MS Razzaque","year":"2006","unstructured":"Razzaque MS  et al. (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20: 720\u2013722","journal-title":"FASEB J"},{"key":"BFncpneph0189_CR40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/01.hjh.0000166849.72721.1c","volume":"23","author":"D Haffner","year":"2005","unstructured":"Haffner D  et al. (2005) Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067\u20131075","journal-title":"J Hypertens"},{"key":"BFncpneph0189_CR41","first-page":"a275","volume":"15","author":"O Phan","year":"2004","unstructured":"Phan O  et al. (2004) Sevelamer prevents accelerated atherosclerosis in apolipoprotein E deficient (apoE-\/-) mice with chronic renal failure (CRF) 5. J Am Soc Nephrol 15: a275 (Poster FPO962)","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR42","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1046\/j.1523-1755.2003.00284.x","volume":"64","author":"M Cozzolino","year":"2003","unstructured":"Cozzolino M  et al. (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653\u20131661","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR43","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M  et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446\u2013456","journal-title":"N Engl J Med"},{"key":"BFncpneph0189_CR44","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0140-6736(76)92220-0","volume":"1","author":"L Tougaard","year":"1976","unstructured":"Tougaard L  et al. (1976) Controlled trial of 1alpha-hydroxycholecalciferol in chronic renal failure. Lancet 1: 1044\u20131047","journal-title":"Lancet"},{"key":"BFncpneph0189_CR45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(78)92702-2","volume":"2","author":"C Christiansen","year":"1978","unstructured":"Christiansen C  et al. (1978) Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 2: 700\u2013703","journal-title":"Lancet"},{"key":"BFncpneph0189_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000190244","volume":"77","author":"DJ Goldsmith","year":"1997","unstructured":"Goldsmith DJ  et al. (1997) Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77: 37\u201343","journal-title":"Nephron"},{"key":"BFncpneph0189_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1042\/cs0850309","volume":"85","author":"M Marangella","year":"1993","unstructured":"Marangella M  et al. (1993) Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients. Clin Sci (Lond) 85: 309\u2013314","journal-title":"Clin Sci (Lond)"},{"key":"BFncpneph0189_CR48","doi-asserted-by":"crossref","unstructured":"Qunibi WY (2005) Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int Suppl: S43\u2013S50","DOI":"10.1111\/j.1523-1755.2005.09507.x"},{"key":"BFncpneph0189_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM  et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245\u2013252","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR50","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London GM  et al. (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943\u20131951","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000184864","volume":"48","author":"H Renaud","year":"1988","unstructured":"Renaud H  et al. (1988) Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron 48: 28\u201332","journal-title":"Nephron"},{"key":"BFncpneph0189_CR52","first-page":"131","volume-title":"Advances in Nephrology Year-Book","author":"A Fournier","year":"1997","unstructured":"Fournier A  et al. (1997) The clinical significance of adynamic bone disease in uremia. In Advances in Nephrology Year-Book, vol 27, 131\u2013166 (Ed Gr\u00fcnfeld JP). St Louis: Mosby"},{"key":"BFncpneph0189_CR53","first-page":"SP244","volume":"101","author":"J Mansour","year":"2005","unstructured":"Mansour J  et al. (2005) Vascular calcifications, oral calcium dose and mortality of hemodialysis patients: any causal relationship? Nephrol Dial Transplant 101: SP244","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0189_CR54","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0272-6386(96)90363-7","volume":"27","author":"J Braun","year":"1996","unstructured":"Braun J  et al. (1996) Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394\u2013401","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0189_CR55","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M  et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115\u20131125","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR56","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","volume":"45","author":"RE LaClair","year":"2005","unstructured":"LaClair RE  et al. (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026\u20131033","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0189_CR57","doi-asserted-by":"crossref","unstructured":"Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80: 1678S\u20131688S","DOI":"10.1093\/ajcn\/80.6.1678S"},{"key":"BFncpneph0189_CR58","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1161\/01.CIR.0000160353.27927.70","volume":"111","author":"D Somjen","year":"2005","unstructured":"Somjen D  et al. (2005) 25-hydroxyvitamin D3-1\u03b1-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111: 1666\u20131671","journal-title":"Circulation"},{"key":"BFncpneph0189_CR59","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R  et al. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823\u20132828","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR60","first-page":"241","volume":"11","author":"A Fournier","year":"1982","unstructured":"Fournier A  et al. (1982) Prevention and medical treatment of hyperparathyroidism secondary to renal failure in the adult. In Advances in Nephrology, vol 11, 241\u2013268 (Ed Hamburger J) Chicago: YearBook Medical Publisher","journal-title":"Advances in Nephrology"},{"key":"BFncpneph0189_CR61","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/ndt\/17.11.1875","volume":"17","author":"JB Cannata-Andia","year":"2002","unstructured":"Cannata-Andia JB and Gomez Alonso C (2002) Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 17: 1875\u20131878","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0189_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1681\/ASN.V3196","volume":"3","author":"JA Delmez","year":"1992","unstructured":"Delmez JA  et al. (1992) Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3: 96\u2013102","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000187207","volume":"63","author":"F Ben Hamida","year":"1993","unstructured":"Ben Hamida F  et al. (1993) Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate-binder. Nephron 63: 258\u2013262","journal-title":"Nephron"},{"key":"BFncpneph0189_CR64","first-page":"a271","volume":"15","author":"J Damment","year":"2004","unstructured":"Damment J  et al. (2004) The bone kinetics of lanthanum in dialysis patient treated with lanthanum carbonate up to 4.5 years. J Am Soc Nephrol 15: a271 (Poster FPO 948)","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0189_CR65","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","volume":"67","author":"B Lacour","year":"2005","unstructured":"Lacour B  et al. (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062\u20131069","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR66","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","volume":"65","author":"Y Takahashi","year":"2004","unstructured":"Takahashi Y  et al. (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099\u20131104","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR67","doi-asserted-by":"publisher","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","volume":"82","author":"DM Capuzzi","year":"1998","unstructured":"Capuzzi DM  et al. (1998) Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82: 74U\u201381U","journal-title":"Am J Cardiol"},{"key":"BFncpneph0189_CR68","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/j.1523-1755.2005.00583_8.x","volume":"68","author":"JB Rottembourg","year":"2005","unstructured":"Rottembourg JB  et al. (2005) Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68: 2911\u20132912","journal-title":"Kidney Int"},{"key":"BFncpneph0189_CR69","doi-asserted-by":"crossref","unstructured":"Rutkowski B  et al. (2003) N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl: S19\u2013S21","DOI":"10.1046\/j.1523-1755.63.s84.36.x"},{"key":"BFncpneph0189_CR70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrd1718","volume":"4","author":"P Jagtap","year":"2005","unstructured":"Jagtap P and Szabo C (2005) Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421\u2013440","journal-title":"Nat Rev Drug Discov"},{"key":"BFncpneph0189_CR71","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","volume":"66","author":"B Manns","year":"2004","unstructured":"Manns B  et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239\u20131247","journal-title":"Kidney Int"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0189","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T20:38:18Z","timestamp":1650055098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6,1]]}},"alternative-id":["BFncpneph0189"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0189","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}